Full-Time

Digital Product Owner-Global Access Solution

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$133k - $209k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Cambridge, MA, USA

Category
Product Management
Product
Required Skills
Agile
UI/UX Design
Salesforce
Development Operations (DevOps)
Requirements
  • Degree in Computer Science/Business Informatics or other relevant graduate degree required
  • Experience as a Service/Success Manager with software products
  • Experience as a Subject Matter Expert for Medical Patient Access products and solutions
  • Experience conveying current technology trends, excellent feel for exceptional user experiences and design
  • Experience with Salesforce products like Marketing Cloud, Data Cloud, Health Cloud, Sales Cloud, Service Cloud, Mulesoft and related products
  • Experience with Veeva CRM and Vault platform preferred
  • Experience in agile and SAFE methodologies and software development lifecycle
  • Strong communication skills with ability to articulate and optimize design based on the value to the user and the business, lead ideation sessions and workshops
  • Experience working in a life sciences environment and/or familiarity with Takeda strongly preferred
Responsibilities
  • Act as a single point of contact for DD&T Global Medical / Global Medical and Patient Services teams when designing solutions on the Medical Patient Access product/platforms
  • Define and maintain the Medical Patient Access product vision and roadmap aligned with Takeda’s strategic goals
  • Engage with healthcare professionals, compliance teams, and business leaders to understand needs and gather requirements. Act as the primary liaison between development teams and stakeholders
  • Ensure the OPA system adheres to all applicable healthcare regulations / standards. Incorporate secure data handling and patient confidentiality measures into product features
  • Create, refine, and prioritize the product backlog to ensure timely delivery of high-impact features. Balance technical constraints with user and business needs
  • Collaborate with UX/UI teams to design intuitive workflows that enhance patient and healthcare provider engagement. Gather user feedback to iterate on and improve system usability
  • Enable and support teams in leveraging OPA data for improved decision-making and patient care
  • Define KPIs for OPA success, including customer satisfaction, operational efficiency, and system adoption. Analyze performance metrics to guide continuous product improvement
  • Drive cross-functional team efforts, ensuring alignment with the overall Takeda platform / product OPA vision
  • Develop and oversee training programs to ensure end-user adoption and optimal use of the OPA system. Provide ongoing support to address user challenges and refine the product
  • Ensure application of agile and DevOps principles in service delivery
Desired Qualifications
  • Familiarity with regulated systems – general level of understanding of computer systems validation (GxP)
  • Experience as a Enablement Lead / Manager with software products

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized in all operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...